Posted by Michael Wonder on 15 Aug 2022
argenx announces European Commission approval of Vyvgart (efgartigimod alfa-fcab) for the treatment of generalised myasthenia gravis
11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
argenx today announced that the European Commission has granted marketing authorisation for Vvygart (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.
